

PERSONAL INFORMATION

Lydia Scarfò

 +390226436119

Sex Female | Date of birth 12/MAR/1981 | Nationality Italian

CURRENT POSITION

Associate Professor, Internal Medicine, Università Vita-Salute San Raffaele, Via Olgettina 58, 20132 Milano, Italy

WORK EXPERIENCE

01Jan2016- Today

Consultant Hematologist

Prof. Paolo Ghia, Strategic Research Program on CLL, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milano, Italy

▪ In patient and out-patient clinic

Lymphoproliferative disorders

01Aug2017 – 31Jul2025

Assistant Professor

Internal Medicine, Università Vita Salute San Raffaele, Via Olgettina 58, 20132 Milano, Italy

20Mar2012 – 31Dec2015

Consultant Hematologist

Prof. Federico Caligaris-Cappio, Department of Oncohematology, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milano, Italy

▪ In patient and out-patient clinic

Lymphoproliferative disorders

01Jul2012 – 31Jul2017

Internal Medicine Trainee

Prof. Federico Caligaris Cappio, Internal Medicine, Università Vita Salute San Raffaele, Via Olgettina 58, 20132 Milano, Italy

▪ In patient and out patient clinic

Acute leukemias, myeloproliferative disorders, lymphoproliferative disorders, non malignant hematology

March 2008 – 19Mar2012

Haematology Trainee

Prof. Antonio Cuneo, Hematology Section, Università degli Studi di Ferrara, Corso Giovecca 203, 44100 Ferrara, Italy

▪ In patient and out patient clinic

Acute leukemias, myeloproliferative disorders, lymphoproliferative disorders, non malignant hematology

EDUCATION AND TRAINING

February 2008 – March 2012

Visiting Fellow

Laboratory of Lymphoid Malignancies, Division of Molecular Oncology, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milano, Italy.

▪ Lymphoproliferative disorders

December 2006 – March

Volunteer Medical Doctor

2008

Prof. Antonio Cuneo, Hematology Section, Università degli Studi di Ferrara, Corso Giovecca 203, 44100 Ferrara, Italy

- Acute leukemias, myeloproliferative disorders, lymphoproliferative disorders, non malignant hematology

September 2002 – February 2003

Visiting Student

Anatomy Section, Department of Morphology and Embriology, Università degli Studi di Ferrara, Corso Giovecca 203, 44100 Ferrara, Italy

- Molecular biology, flow cytometry

September 2002 – February 2003

Visiting Student

Histology Section, Department of Morphology and Embriology, Università degli Studi di Ferrara, Corso Giovecca 203, 44100 Ferrara, Italy

- Molecular biology, flow cytometry

Sep 2000 – Dec 2006

Medical Doctor Degree

Università degli Studi di Ferrara, Corso Giovecca 203, 44100 Ferrara, Italy

- Medicine

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B1	B1	B2
German	B1	A2	A2	A2	A2

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user
Common European Framework of Reference for Languages

Organisational / managerial skills

- Coordinating activity of observational and interventional national clinical trials
- Design and management of electronic clinical case forms

Job-related skills

- Experienced in conducting phase I, II, III, IV clinical trials

ADDITIONAL INFORMATION

Publications See Annexes

Memberships European Hematology Association (EHA) member
European Research Initiative on CLL (ERIC) member

ANNEXES

Selected list of publications

1. **Scarfò L**, Dagklis A, Scielzo C, Fazi C, Ghia P. CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? Semin Cancer

- Biol. 2010 Dec;20(6):384-90.
2. Fazi C, Dagklis A, Cottini F, **Scarfò L**, Bertilaccio MT, Finazzi R, Memoli M, Ghia P. Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals. *Cytometry B Clin Cytom.* 2010;78 Suppl 1:S61-8.
3. Scielzo C, Apollonio B, **Scarfò L**, Janus A, Muzio M, Ten Hacken E, Ghia P, Caligaris-Cappio F. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. *Leukemia.* 2011 Nov;25(11):1760-7.
4. Fazi C, **Scarfò L**, Pecciarini L, Cottini F, Dagklis A, Janus A, Talarico A, Scielzo C, Sala C, Toniolo D, Caligaris-Cappio F, Ghia P. General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. *Blood.* 2011 Dec 15;118(25):6618-25.
5. **Scarfò L**, Zibellini S, Tedeschi A, Maura F, Neri A, Bertazzoni P, Sarina B, Nalli G, Motta M, Rossini F, Cortelezzi A, Montillo M, Orlandi E, Ghia P. Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines? *Leukemia.* 2012 Jul;26(7):1703-7.
6. Ponzoni M, Kanellis G, Pouliou E, Baliakas P, **Scarfò L**, Ferreri AJ, Doglioni C, Bikos V, Dagklis A, Anagnostopoulos A, Ghia P, Stamatopoulos K, Papadaki T. Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology? *Am J Surg Pathol.* 2012 Nov;36(11):1609-18.
7. Fonte E, Apollonio B, **Scarfò L**, Ranghetti P, Fazi C, Ghia P, Caligaris-Cappio F, Muzio M. In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors. *Clin Cancer Res.* 2013 Jan 15;19(2):367-79.
8. ten Hacken E, Scielzo C, Bertilaccio MT, **Scarfò L**, Apollonio B, Barbaglio F, Stamatopoulos K, Ponzoni M, Ghia P, Caligaris-Cappio F. Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. *Blood.* 2013 Mar 21;121(12):2264-73.
9. Apollonio B, Scielzo C, Bertilaccio MT, Ten Hacken E, **Scarfò L**, Ranghetti P, Stevenson F, Packham G, Ghia P, Muzio M, Caligaris-Cappio F. Targeting B-cell anergy in chronic lymphocytic leukemia. *Blood.* 2013 May 9;121(19):3879-88, S1-8.
10. Strefford JC, Sutton LA, Baliakas P, Agathangelidis A, Malčiková J, Plevova K, **Scarfò L**, Davis Z, Stalika E, Cortese D, Cahill N, Pedersen LB, di Celle PF, Tzenou T, Geisler C, Panagiotidis P, Langerak AW, Chiorazzi N, Pospisilova S, Oscier D, Davi F, Belessi C, Mansouri L, Ghia P, Stamatopoulos K, Rosenquist R. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. *Leukemia.* 2013 Nov;27(11):2196-9.
11. **Scarfò L**, Fazi C, Ghia P. MBL versus CLL: how important is the distinction? *Hematol Oncol Clin North Am.* 2013 Apr;27(2):251-65.
12. Vardi A, Dagklis A, **Scarfò L**, Jelinek D, Newton D, Bennett F, Almeida J, Rodriguez-Caballero A, Allgood S, Lanasa M, Cortelezzi A, Orlandi E, Veronese S, Montillo M, Rawstron A, Shanafelt T, Orfao A, Stamatopoulos K, Ghia P. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. *Blood.* 2013 May 30;121(22):4521-8.
13. Karube K, **Scarfò L**, Campo E, Ghia P. Monoclonal B cell lymphocytosis and "in situ" lymphoma. *Semin Cancer Biol.* 2014 Feb;24:3-14.
14. **Scarfò L**, Ghia P. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. *Immunol Lett.* 2013 Sep-Oct;155(1-2):36-9.
15. Vardi A, Agathangelidis A, Sutton LA, Chatzouli M, **Scarfò L**, Mansouri L, Douka V, Anagnostopoulos A, Darzentas N, Rosenquist R, Ghia P, Belessi C, Stamatopoulos K. IgG-switched CLL has a distinct immunogenetic signature from the common MD variant: ontogenetic implications. *Clin Cancer Res.* 2014 Jan 15;20(2):323-30.
16. Messina C, Ferreri AJ, Govi S, Bruno-Ventre M, Gracia Medina EA, Porter D, Radford J, Heo DS, Park HY, Pro B, Jayamohan J, Visco C, **Scarfò L**, Zucca E, Gospodarowicz M, Christie D; International Extranodal Lymphoma Study Group (I.E.L.S.G.). Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). *Br J Haematol.* 2014 Mar;164(6):834-40.
17. Bruno Ventre M, Ferreri AJ, Gospodarowicz M, Govi S, Messina C, Porter D, Radford J, Heo DS, Park Y, Martinelli G, Taylor E, Lucraft H, Hong A, **Scarfò L**, Zucca E, Christie D; International Extranodal Lymphoma Study Group. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). *Oncologist.* 2014 Mar;19(3):291-8.
18. Malcikova J, Stalika E, Davis Z, Plevova K, Trbusek M, Mansouri L, **Scarfò L**, Baliakas P, Gardiner A, Sutton LA, Francova HS, Agathangelidis A, Anagnostopoulos A, Tracy I, Makris A, Smardova J, Ghia P, Belessi C, Gonzalez D, Rosenquist R, Oscier D, Pospisilova S, Stamatopoulos K. The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors. *Br J Haematol.* 2014 Aug;166(4):621-5.
19. Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, **Scarfò L**, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R; European Research Initiative on CLL (ERIC). Recurrent mutations refine prognosis in chronic lymphocytic leukemia. *Leukemia.* 2015 Feb;29(2):329-36.
20. Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, **Scarfò L**, Sassone M, Govi S, Caligaris-Cappio F. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. *Br J Haematol.* 2015 Mar;168(5):654-62.
21. Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, **Scarfò L**, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, Moreno D, Van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. *Blood.* 2015 Jan 29;125(5):856-9.
22. Ferreri AJ, Sassone M, Kiesewetter B, Govi S, **Scarfò L**, Donadoni G, Raderer M. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. *Ann Oncol.* 2015 Aug;26(8):1760-5.
23. Agathangelidis A, **Scarfò L**, Barbaglio F, Apollonio B, Bertilaccio MT, Ranghetti P, Ponzoni M, Leone G, De Pascali V, Pecciarini L, Ghia P, Caligaris-Cappio F, Scielzo C. Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia

- Cell Line. *PLoS One*. 2015 Jun 25;10(6):e0130195.
24. Baliakas P, Hadzidimitriou A, Agathangelidis A, Rossi D, Sutton LA, Kminkova J, **Scarfo L**, Pospisilova S, Gaidano G, Stamatopoulos K, Ghia P, Rosenquist R. Prognostic relevance of MYD88 mutations in CLL: the jury is still out. *Blood*. 2015 Aug 20;126(8):1043-4.
 25. Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, **Scarfo L**, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M; Rete Ematologica Lombarda (REL)-CLL workgroup. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. *Haematologica*. 2015 Dec;100(12):e501-4.
 26. Fonte E, Agathangelidis A, Reverberi D, Ntoufa S, **Scarfo L**, Ranghetti P, Cutrona G, Tedeschi A, Xochelli A, Caligaris-Cappio F, Ponzoni M, Belessi C, Davis Z, Piris MA, Oscier D, Ghia P, Stamatopoulos K, Muzio M. Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. *Haematologica*. 2015 Nov;100(11):1460-8.
 27. Valsecchi R, Coltella N, Belloni D, Ponente M, Ten Hacken E, Scielzo C, **Scarfo L**, Bertilaccio MT, Brambilla P, Lenti E, Martinelli Boneschi F, Brendolan A, Ferrero E, Ferrarini M, Ghia P, Tonon G, Ponzoni M, Caligaris Cappio F, Bernardi R. HIF-1 α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. *Blood*. 2016 Apr 21; 127(16):1987-97.
 28. **Scarfo L**, Ghia P. What does it mean I have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges. *Semin Oncol*. 2016 Apr;43(2):201-8.
 29. Sutton LA, Young E, Baliakas P, Hadzidimitriou A, Moysiadis T, Plevova K, Rossi D, Kminkova J, Stalika E, Pedersen LB, Malcikova J, Agathangelidis A, Davis Z, Mansouri L, **Scarfo L**, Boudjoghra M, Navarro A, Muggen AF, Yan XJ, Nguyen-Khac F, Larrayoz M, Panagiotidis P, Chiorazzi N, Niemann CU, Belessi C, Campo E, Strefford JC, Langerak AW, Oscier D, Gaidano G, Pospisilova S, Davi F, Ghia P, Stamatopoulos K, Rosenquist R; ERIC, the European Research Initiative on CLL. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. *Haematologica*. 2016 Aug;101(8):959-67.
 30. Bianco M, Gasparri A, Generoso L, Assi E, Colombo B, **Scarfo L**, Bertilaccio MT, Scielzo C, Ranghetti P, Dondossola E, Ponzoni M, Caligaris-Cappio F, Ghia P, Corti A. Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models. *Oncotarget*. 2016 Jul 5;7(27):41725-41736.
 31. **Scarfo L**, Ferreri AJ, Ghia P. Chronic lymphocytic leukaemia. *Crit Rev Oncol Hematol*. 2016 Aug;104:169-82.
 32. McMahon KM, Scielzo C, Angeloni NL, Deiss-Yehiely E, **Scarfo L**, Ranghetti P, Ma S, Kaplan J, Barbaglio F, Gordon LI, Giles FJ, Thaxton CS, Ghia P. Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. *Oncotarget*. 2017 Feb 14;8(7):11219-11227.
 33. Ghia P, **Scarfo L***, Perez S, Pathiraja K, Derosier M, Small K, McCrary Sisk C, Patton N. Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia. *Blood*. 2017 Mar 30;129(13):1876-1878.
 34. Ferreri AJ, Sassone M, Zaja F, Re A, Spina M, Rocco AD, Fabbri A, Stelitano C, Frezzato M, Rusconi C, Zambello R, Couto S, Ren Y, Arcari A, Bertoldo G, Nonis A, **Scarfo L**, Calimeri T, Cecchetti C, Chiozzotto M, Govi S, Ponzoni M. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. *Lancet Haematol*. 2017 Mar;4(3):e137-e146.
 35. Vilia MG, Fonte E, Veliz Rodriguez T, Tocchetti M, Ranghetti P, **Scarfo L**, Papakonstantinou N, Ntoufa S, Stamatopoulos K, Ghia P, Muzio M. The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia. *Leuk Lymphoma*. 2017 Oct;58(10):2419-2425.
 36. Gorini F, Azzimonti L, Delfanti G, **Scarfo L**, Scielzo C, Bertilaccio MT, Ranghetti P, Gulino A, Doglioni C, Di Napoli A, Capri M, Franceschi C, Caligaris-Cappio F, Ghia P, Bellone M, Dellabona P, Casorati G, de Lalla C. Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. *Blood*. 2017 Jun 29;129(26):3440-3451.
 37. Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt T, Plevova K, Boudjogha M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, **Scarfo L**, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan-Djuraevic T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann C, Döhner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K. Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. *Clin Cancer Res*. 2017 Sep 1;23(17):5292-5301.
 38. Minici C, Gounari M, Übelhart R, **Scarfo L**, Dühren-von Minden M, Schneider D, Tasdogan A, Alkhatib A, Agathangelidis A, Ntoufa S, Chiorazzi N, Jumaa H, Stamatopoulos K, Ghia P, Degano M. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. *Nat Commun*. 2017 Jun 9;8:15746.
 39. Hacken ET, Gounari M, Back JW, Shimanovskaya E, **Scarfo L**, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JA. Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. *Haematologica*. 2017 Oct;102(10):e394-e396.
 40. Fonte E, Vilia MG, Reverberi D, Sana I, **Scarfo L**, Ranghetti P, Orfanelli U, Cenci S, Cutrona G, Ghia P, Muzio M. Toll-like receptor 9 stimulation can induce I κ B ζ expression and IgM secretion in chronic lymphocytic leukemia cells. *Haematologica*. 2017 Nov;102(11):1901-1912.
 41. Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, **Scarfo L**, Davis Z, Yan XJ, Plevova K, Sandberg Y, Vojdeman FJ, Tzenou T, Chu CC, Veronese S, Mansouri L, Smedby KE, Giudicelli V, Nguyen-Khac F, Panagiotidis P, Juliusson G, Anagnostopoulos A, Lefranc MP, Trentin L, Catherwood M, Montillo M, Niemann CU, Langerak AW, Pospisilova S, Stavroyianni N, Chiorazzi N, Oscier D, Jelinek DF, Shanafelt T, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K. No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. *Haematologica*. 2018 Apr;103(4):e158-e161.
 42. Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, Mattsson M, Sutton LA, Minga E, **Scarfo L**, Rossi D, Davis Z, Villamor N, Parker H, Kotaskova J, Stalika E, Plevova K, Mansouri L, Cortese D, Navarro A, Delgado J, Larrayoz M, Young E, Anagnostopoulos A, Smedby KE, Juliusson G, Sheehy O, Catherwood M, Strefford JC, Stavroyianni N, Belessi C,

- Pospisilova S, Oscier D, Gaidano G, Campo E, Haferlach C, Ghia P, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC). Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. *Haematologica*. 2019 Feb;104(2):360-369. doi: 10.3324/haematol.2018.195032.
43. Gounari M, Ntoufa S, Gerousi M, Vilja MG, Moysiadi T, Kotta K, Papakonstantinou N, **Scarfò L**, Agathangelidis A, Fonte E, Ranghetti P, Nenou A, Xochelli A, Coscia M, Tedeschi A, Stavroyanni N, Muzio M, Stamatopoulos K, Ghia P. Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment. *Leukemia*. 2019 Apr;33(4):1030-1051. doi: 10.1038/s41375-018-0335-2.
44. Petrov P, Sarapulov AV, Eöry L, Scielzo C, **Scarfò L**, Smith J, Burt DW, Mattila PK. Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control. *Sci Rep*. 2019 Mar 11;9(1):4155. doi: 10.1038/s41598-019-40697-1.
45. Steurer M, Montillo M, **Scarfò L**, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A, Burgstaller S, Frömming A, Dümmler T, Riecke K, Baumann M, Beyer D, Vauléon S, Ghia P, Foà R, Caligaris-Cappio F, Gobbi M. Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. *Haematologica*. 2019 Oct;104(10):2053-2060. doi: 10.3324/haematol.2018.205930.
46. Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L, Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatìci A, Ciolli S, Coscia M, Sportoletti P, Murru R, Levato L, Gentile M, D'Arena G, Efremov DG, Tedeschi A, **Scarfò L**, Cuneo A, Foà R, Laurenti L. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. *Br J Haematol*. 2019 Oct;187(1):e8-e11. doi: 10.1111/bjh.16123.
47. Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, **Scarfò L**, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. *Cancer Immunol Res*. 2019 Dec;7(12):2036-2051. doi: 10.1158/2326-6066.CIR-19-0152.
48. Schiattone L, Ghia P, **Scarfò L**. The evolving treatment landscape of chronic lymphocytic leukemia. *Curr Opin Oncol*. 2019 Nov;31(6):568-573. doi: 10.1097/CCO.0000000000000585.
49. **Scarfò L**, Tedeschi A. Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia - Time to Retire? *Hemasphere*. 2019 Aug 7;3(4):e278. doi: 10.1097/HS9.0000000000000278. eCollection 2019 Aug.
50. Carlo-Stella C, Delarue R, **Scarfò L**, Barde PJ, Nair A, Locatelli SL, Morello L, Magagnoli M, Vakkalanka S, Viswanadha S, Ferreri AJM. A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study. *Clin Lymphoma Myeloma Leuk*. 2019 Oct 23. pii: S2152-2650(19)32061-0. doi: 10.1016/j.clml.2019.10.013. [Epub ahead of print]
51. Heltai S, Ghia P, **Scarfò L**. Relevance of Minimal Residual Disease in the Era of Targeted Agents. *Cancer J*. 2019 Nov/Dec;25(6):410-417. doi: 10.1097/PPO.0000000000000413.
52. Barbaglio F, Belloni D, **Scarfò L**, Sbrana FV, Ponzoni M, Bongiovanni L, Pavesi L, Zambroni D, Stamatopoulos K, Caiola VR, Ferrero E, Ghia P, Scielzo C. Three - dimensional co - culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient - specific response to mobilizing agents *HAEMATOLOGICA* 2021 106 9 2334 2344 10.3324/haematol.2020.248112
53. Meyerheim M, Karamanidou C, Payne S, Garani - Papadatos T, Sander A, Downing J, Stamatopoulos K, Ling J, Payne C, **Scarfò L**, Lokaj P, Maramis C, Graf N. MyPal - Child study protocol: an observational prospective clinical feasibility study of the MyPal ePRO - based early palliative care digital system in paediatric oncology patients *BMJ OPEN* 2021 11 4 e045226 10.1136/bmjopen - 2020 - 045226
54. Ghia P, Dlugosz - Danecka M, **Scarfò L**, Jurczak W. Acalabrutinib: a highly selective potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia *LEUKEMIA & LYMPHOMA* 2021 62 5 1066 1076 10.1080/10428194.2020.1864352
55. Benedetti E, Barate C, Bruno B, Bramanti E, Ghia P, **Scarfò L**, Morganti R, Ricchiuto V, Galimberti S. Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography *LEUKEMIA RESEARCH* 2021 100 106488 10.1016/j.leukres.2020.106488
56. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martín - Moro F, Razanamahery J, Riches JC, Zwicker J, Patell R, Vekemans MC, **Scarfò L**, Chatzikonstantinou T, Yildiz H, Lattenist R, Mantzaris I, Wood WA, Hicks LK. Outcomes of patients with hematologic malignancies and COVID - 19: a systematic review and meta - analysis of 3377 patients *BLOOD* 2020 136 25 2881 2892 10.1182/blood.2020008824
57. Fiorcari S, Maffei R, Vallerini D, **Scarfò L**, Barozzi P, Maccaferri M, Potenza L, Ghia P, Luppi M, Marasca R. BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia *FRONTIERS IN IMMUNOLOGY* 2020 11 2158 10.3389/fimmu.2020.02158
58. Cuneo A, **Scarfò L**, Reda G, Varettoni M, Quaglia FM, Marchetti M, De Paoli L, Re F, Pietrasanta D, Rigolin GM, Orsucci L, Ibatìci A, Gattei V, Mauro FR, Trentin L, Laurenti L, Marasca R, Foà R. Chronic lymphocytic leukemia management in Italy during the COVID - 19 pandemic: a Campus CLL report *BLOOD* 2020 136 6 763 766 10.1182/blood.2020006854
59. Reda G, Noto A, Cassin R, Zamproga G, Borella C, **Scarfò L**, Farina L, Molteni A, Ghia P, Tedeschi A, Montillo M. Reply to CLL and COVID - 19 at the Hospital Clinic of Barcelona: an interim report Analysis of six hematological centers in Lombardy On behalf of CLL commission of Lombardy Hematology Network (REL) *LEUKEMIA* 2020 34 9 2531 2532 10.1038/s41375 - 020 - 0966 - y
60. **Scarfò L**, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia - Marco JA, Hernández - Rivas JA, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar - García C, Itchaki G, Spacek M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Simkovic M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik - Szczepanek E, Ruchlmer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Pareja MO, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyanni N, Strugov V, Tam C, Zdrenghea M, Coscia M,

- Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P. COVID - 19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC the European Research Initiative on CLL and CLL Campus LEUKEMIA 2020 34 9 2354 2363 10.1038/s41375-020-0959-x
61. Valsecchi K, Coltella N, Magliulo D, Bongiovanni L, **Scarfò L**, Ghia P, Ponzoni M, Demardi R EZN - 2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine OPEN BIOLOGY 2020 10 5 10.1098/rsob.190262
 62. Delvecchio VS, Sana I, Mantione ME, Vilia MG, Ranghetti P, Rovida A, Angelillo P, **Scarfò L**, Ghia P, Muzio M. Interleukin - 1 receptor - associated kinase 4 inhibitor interrupts toll - like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis BRITISH JOURNAL OF HAEMATOLOGY 2020 189 3 475 488 10.1111/bjh.16386
 63. Carlo - Stella C, Delarue R, **Scarfò L**, Barde PJ, Nair A, Locatelli SL, Morello L, Magagnoli M, Vakkalanka S, Viswanadha S, Ferreri AJM. A First - in - human Study of Tenalisib (RP6530) a Dual PI3K δ/γ Inhibitor in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2020 20 2 78 86 10.1016/j.clml.2019.10.013
 64. Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, Ghia P, Gökbuget N, González - Calle V, Huntly B, Jäger U, Latino NJ, Douillard JY, Malcovati L, Mateos MV, Ossenkoppele GJ, Porkka K, Raderer M, Ribera JM, **Scarfò L**, Wester R, Zygoura P, Sonneveld P. EHA evaluation of the ESMO - Magnitude of Clinical Benefit Scale version 1.1 (ESMO - MCBS v1.1) for haematological malignancies ESMO OPEN 2020 5 1 e000611 10.1136/esmoopen-2019-000611
 65. Innocenti I, Reda G, Visentin A, Coscia M, Motta M, Murru R, Moia R, Gentile M, Pennese E, Quaglia FM, Albano F, Cassin R, Deodato M, Ielo C, Frustaci AM, Piciocchi A, Rughini A, Arena V, Di Sevo D, Tomasso A, Autore F, Del Poeta G, **Scarfò L**, Mauro FR, Tedeschi A, Trentin L, Pompili M, Foà R, Ghia P, Cuneo A, Laurenti L Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study HAEMATOLOGICA 2022 107 6 1470 1473 10.3324/haematol.2021.280325
 66. Koumakis L, Schera F, Parker H, Bonotis P, Chatzimina M, Argyropaidas P, Zacharioudakis G, Schäfer M, Kakalou C, Karamanidou C, Didi J, Kazantzaki E, **Scarfò L**, Marias K, Natsiavas P. Fostering Palliative Care Through Digital Intervention: A Platform for Adult Patients With Hematologic Malignancies FRONTIERS IN DIGITAL HEALTH 2021 3 730722 10.3389/fdgth.2021.730722
 67. **Scarfò L**, Karamanidou C, Doubek M, Garani - Papadatos T, Didi J, Pontikoglou C, Ling JL, Payne C, Papadaki HA, Rosenquist R, Stavroyianni N, Payne S, Ghia P, Natsiavas P, Maramis C, Stamatopoulos K. MyPal ADULT study protocol: a randomised clinical trial of the MyPal ePRO - based early palliative care system in adult patients with haematological malignancies BMJ OPEN 2021 11 11 e050256 10.1136/bmjopen
 68. Chatzikonstantinou T, Kapetanakis A, **Scarfò L***, Karakatsoulis G, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Bron D, Capasso A, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar - García C, De Paoli L, De Paolis MR, Del Poeta G, Demosthenous C, Dimou M, Donaldson D, Doubek M, Efstathiopoulou M, Eichhorst B, El - Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García - Marco JA, García - Serra R, Gentile M, Gimeno E, Glenthøj A, da Silva MG, Gutwein O, Hakobyan YK, Herishanu Y, Hernandez - Rivas JA, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicinska E, Karlsson LK, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez - Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Reda G, Rigolin GM, Ruchlemer R, Saghunyan G, Shrestha A, Simkovic M, Spacek M, Sportoletti P, Stanca O, Stavroyianni N, Tadmor T, Te Raa D, Tonino SH, Trentin L, Van der Spek E, van Gelder M, van Kampen R, Varettoni M, Visentin A, Vitale C, Wasik - Szczepanek E, Wróbel T, San Segundo LY, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Stamatopoulos K, Ghia P. COVID - 19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study LEUKEMIA 2021 35 12 3444 3454 10.1038/s41375-021-01450-8
 69. Cuneo A, Rigolin GM, Coscia M, Quaresmini G, **Scarfò L**, Mauro FR, Motta M, Quaglia FM, Trentin L, Ferrario A, Laurenti L, Reda G, Ferrari A, Pietrasanta D, Sportoletti P, Re F, De Paoli L, Foglietta M, Giordano A, Marchetti M, Farina L, Del Poeta G, Varettoni M, Chiurazzi F, Marasca R, Malerba L, Ibatici A, Tisi MC, Stefoni V, Leone M, Barate C, Olivieri J, Murru R, Gentile M, Sanna A, Gozzetti A, Gattei V, Gottardi D, Derenzini E, Levato L, Orsucci L, Penna G, Chiarenza A, Foà R. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID - 19 pandemic and at the start of the vaccination program. A Campus CLL report HEMATOLOGICAL ONCOLOGY 2021 39 4 570 574 10.1002/hon.2899
 70. Chatzikonstantinou T, Herishanu Y, Montserrat E, Ghia P, Cuneo A, Foà R, **Scarfò L**. COVID - 19 and Chronic Lymphocytic Leukemia Where We Stand Now CANCER JOURNAL 2021 27 4 328 333 10.1097/PPO.0000000000000535
 71. Vitale C, Salvetti C, Griggio V, Porrazzo M, Schiattone L, Zamproga G, Visentin A, Vassallo F, Cassin R, Rigolin GM, Murru R, Laurenti L, Rivela P, Marchetti M, Pennese E, Gentile M, Boccillato E, Perutelli F, Montalbano MC, De Paoli L, Reda G, Orsucci L, Trentin L, Cuneo A, Tedeschi A, **Scarfò L**, Gaidano G, Mauro FR, Foà R, Boccadoro M, Coscia M. Preexisting and treatment - emergent autoimmune cytopenias in patients with CLL treated with targeted drugs BLOOD 2021 137 25 3507 3517 10.1182/blood.2020008201
 72. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales M, Ziv T, Arbel YS, **Scarfò L**, Joffe E, Perry C, Ghia P. Efficacy of the BNT162b2 mRNA COVID - 19 vaccine in patients with chronic lymphocytic leukemia BLOOD 2021 137 23 3165 3173 10.1182/blood.2021011568
 73. Sbrana FV, Pinos R, Barbaglio F, Ribezzi D, Scagnoli F, **Scarfò L**, Redwan IN, Martinez H, Farè S, Ghia P, Scielzo C. 3D Bioprinting Allows the Establishment of Long - Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells FRONTIERS IN IMMUNOLOGY 2021 12 639572 10.3389/fimmu.2021.639572

74. Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M, Plevova K, Davis Z, Yan XJ, Jeromin S, Schneider C, Pedersen LB, Tschumper RC, Sutton LA, Baliakas P, **Scarfò L**, van Gastel EJ, Armand M, Tausch E, Biderman B, Baer C, Bagnara D, Navarro A, de Septenville AL, Guido V, Mitterbauer - Hohendanner G, Dimovski A, Brieghel C, Lawless S, Meggendorfer M, Brazdilova K, Ritgen M, Facco M, Tresoldi C, Visentin A, Patriarca A, Catherwood M, Bonello L, Sudarikov A, Vanura K, Roumelioti M, Francova HS, Moysiadis T, Veronese S, Giannopoulos K, Mansouri L, Karan - Djurasevic T, Sandaltzopoulos R, Böddör C, Fais F, Kater A, Panovska I, Rossi D, Alshemmari S, Panagiotidis P, Costeas P, Espinet B, Antic D, Foroni L, Montillo M, Trentin L, Stavroyianni N, Gaidano G, di Celle PF, Niemann C, Campo E, Anagnostopoulos A, Pott C, Fischer K, Hallek M, Oscier D, Stilgenbauer S, Haferlach C, Jelinek D, Chiorazzi N, Pospisilova S, Lefranc MP, Kossida S, Langerak AW, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K. Higher - order connections between stereotyped subsets: implications for improved patient classification in CLL BLOOD 2021 137 10 1365 1376 10.1182/blood.2020007039
75. Karamanidou C, Xochelli A, Papaioannou M, Moysiadis T, **Scarfò L**, Mattsson M, Stavroyianni N, Rosenquist R, Ghia P, Stamatopoulos K. Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece HEMASPHERE 2021 5 3 e546 10.1097/HS9.0000000000000546
76. Maffei R, Fiorcari S, Atene CG, Martinelli S, **Scarfò L**, Bonfiglio S, Maccaferri M, Ljungström V, Zucchini P, Forghieri F, Potenza L, Ghia P, Marasca R, Trenti T, Tagliafico E, Luppi M. A single - tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib LEUKEMIA & LYMPHOMA 2021 62 8 2018 2021 10.1080/10428194.2021.1894643
77. Mauro FR, Della Starza I, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, **Scarfò L**, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, Novi LAD, Proprius MSD, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. High rate of durable responses with undetectable minimal residual disease with front - line venetoclax and rituximab in young fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study HAEMATOLOGICA 2023 108 8 2091 2100 10.3324/haematol.2022.282116
78. **Scarfò L** Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax. HEMATOLOGY - AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM 2022 1 316 322 10.1182/hematology.2022000344
79. Visentin A, Mauro FR, Catania G, Fresa A, Vitale C, Sanna A, Mattiello V, Cibien F, Sportoletti P, Gentile M, Rigolin GM, Quaglia FM, Murru R, Gozzetti A, Molica S, Marchetti M, Pravato S, Angotzi F, Cellini A, **Scarfò L**, Reda G, Coscia M, Laurenti L, Ghia P, Foà R, Cuneo A, Trentin L. Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real - life CLL campus study. FRONTIERS IN ONCOLOGY 2022 12 1033413 10.3389/fonc.2022.1033413
80. Chiodin G, Drennan S, Martino EA, Ondrisova L, Henderson I, del Rio L, Tracy I, D'Avola A, Parker H, Bonfiglio S, **Scarfò L**, Sutton LA, Strefford JC, Forster J, Brake O, Potter KN, Sale B, Lanham S, Mraz M, Ghia P, Stevenson FK, Forconi F. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL. BLOOD ADVANCES 2022 6 18 5494 5504 10.1182/bloodadvances.2021006659
81. **Scarfò L**, Ferrari S, Frustaci AM, Tani M, Bari A, Scarano E, Colia M, Ranghetti P, Angelillo P, Ronchi P, Ponzoni M, Ferreri AJM, Ghia P. Anti - CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial. BLOOD ADVANCES 2022 6 18 5356 5359 10.1182/bloodadvances.2022007138
82. Laurenti L, Gaidano G, Mauro FR, Molica S, Pasqualetti P, **Scarfò L**, Ghia P. What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient - physician Cross - matching Analysis of a Discrete Choice Experiment. HEMASPHERE 2022 6 9 e771 10.1097/HS9.0000000000000771
83. Albi E, Capasso A, Schiattone L, Ghia P, **Scarfò L**. Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia. SEMINARS IN CANCER BIOLOGY 2022 84 329 338 10.1016/j.semcancer.2022.01.009
84. Antic D, Milic N, Chatzikonstantinou T, **Scarfò L**, Otasevic V, Rajovic N, Allsup D, Cabrero AA, Andres M, Gonzales MB, Capasso A, Collado R, Cordoba R, Cuéllar - García C, Correa JG, De Paoli L, De Paolis MR, Del Poeta G, Dimou M, Doubek M, Efstathiopoulou M, El - Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Lopez - Garcia JA, Garcia - Marco JA, Garcia - Serra R, Gentile M, Gimeno E, da Silva MG, Gutwein O, Hakobyan YK, Herishanu Y, Hernández - Rivas JA, Herold T, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicinska E, Kater AP, Kersting S, Koren - Michowitz M, Labrador J, Lad D, Laurenti L, Fresa A, Levin MD, Bastida CM, Malerba L, Marasca R, Marchetti M, Marquet J, Mihaljevic B, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Nunes R, Olivier J, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Reda G, Rigolin GM, Shrestha A, Simkovic M, Smimova S, Spacek M, Sportoletti P, Stanca O, Stavroyianni N, Te Raa D, Tomic K, Tonino S, Trentin L, Van der Spek E, van Gelder M, Varettoni M, Visentin A, Vitale C, Vukovic V, Wasik - Szczepanek E, Wróbel T, San Segundo LY, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Carrier M, Ghia P, Stamatopoulos K. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID - 19: a study of ERIC the European Research Initiative on CLL. JOURNAL OF HEMATOLOGY & ONCOLOGY 2022 15 1 116 10.1186/s13045 - 022 - 01333 - 0
85. Tausch E, Ljungström V, Agathangelidis A, Zapatka M, **Scarfò L**, Jebaraj BMC, Yosifov DY, Müller A, Munugalavada V, Degenhardt JD, Ghia P, Rosenquist R, Stilgenbauer S. Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations. BLOOD 2022 139 22 3340 3344 10.1182/blood.202104550
86. Forestieri G, di Bergamo LT, Deodato M, Frustaci AM, Moia R, Deambroggi C, Rasi S, Autore F, Merli M, Mattarucchi R, Fahrni G, **Scarfò L**, Gussetti D, Bulian P, Zanatta A, Spina V, Brusca G, Pini K, Piffaretti D, Piroso MC, Salehi M, de Almeida JM, Passweg J, Cavalli F, Zucca E, Gerber B, Stussi G, Gattei V, Ghia P, Gregor M, Passamonti F, Laurenti L, Gaidano G, Tedeschi A, Rossi D,

- Condoluci A. Ibrutinib dose intensity in high - risk chronic lymphocytic leukemia. HEMATOLOGICAL ONCOLOGY 2022 40 5 1100 1104 10.1002/hon.3032
87. Marchetti M, Vitale C, Rigolin GM, Vasile A, Visentin A, **Scarfò L**, Coscia M, Cuneo A. Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real - World Evidence. JOURNAL OF CLINICAL MEDICINE 2022 11 8 2076 10.3390/jcm11082076
 88. Voso MT, Pandzic T, Falconi G, Dencic - Fekete M, De Bellis E, **Scarfò L**, Ljungström V, Iskas M, Del Poeta G, Ranghetti P, Laidou S, Cristiano A, Plevova K, Imbergamo S, Engvall M, Zucchetto A, Salvetti C, Mauro FR, Stavroyianni N, Cavelier L, Ghia P, Stamatopoulos K, Fabiani E, Baliakas P. Clonal haematopoiesis as a risk factor for therapy - related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo - (immuno)therapy. BRITISH JOURNAL OF HAEMATOLOGY 2022 198 1 103 113 10.1111/bjh.18129
 89. Bonfiglio F, Bruscaggini A, Guidetti F, di Bergamo LT, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso MC, Cittone MG, Aribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Buehler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, da Silva MG, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, Lopez - Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza F, Pizzolitto S, Rambaldi A, Sabbatini E, Salles G, Santambrogio E, **Scarfò L**, Stathis A, Stüssi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani PL, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, De Leval L, Dimhofer S, Pileri SA, Piris MA, Traverse - Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Genetic and phenotypic attributes of splenic marginal zone lymphoma. BLOOD 2022 139 5 732 747 10.1182/blood.2021012386
 90. Visentin A, Mauro FR, Cibien F, Vitale C, Reda G, Fresa A, Ciolli S, Pietrasanta D, Marchetti M, Murru R, Gentile M, Rigolin GM, Quaglia FM, **Scarfò L**, Sportoletti P, Pravato S, Piazza F, Coscia M, Laurenti L, Molica S, Foà R, Cuneo A, Trentin L. Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real - life campus CLL study. AMERICAN JOURNAL OF HEMATOLOGY 2022 97 3 E95 E99 10.1002/ajh.26437
 91. Chatzikonstantinou T, **Scarfò L***, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, Kotaskova J, Demosthenous C, Smolej L, Mulligan S, Alcoceba M, Al - Shemari S, Aurran - Schleinitz T, Bacchiari F, Bellido M, Bijou F, Calleja A, Medina A, Khan MA, Cassin R, Chatzileontiadou S, Collado R, Christian A, Davis Z, Dimou M, Donaldson D, Dos Santos G, Dreta B, Efsthathopoulou M, El - Ashwah S, Enrico A, Fresa A, Galimberti S, Galitza A, García - Serra R, Gimeno E, González - Gascón - Y - Marín I, Gozzetti A, Guarente V, Guieze R, Gogia A, Gupta R, Harrop S, Hatzimichael E, Herishanu Y, Hernández - Rivas JA, Inchiappa L, Jaksic O, Janssen S, Kalicinska E, Kamel L, Karakus V, Kater AP, Kho B, Kislova M, Konstantinou E, Koren - Michowitz M, Kotsianidis I, Kreitman RJ, Labrador J, Lad D, Levin MD, Levy I, Longval T, Lopez - Garcia A, Marquet J, Martin - Rodríguez L, Maynadié M, Maslejova S, Mayor - Bastida C, Mihaljevic B, Milosevic I, Miras F, Moia R, Morawska M, Murru R, Nath UK, Navarro - Bailón A, Oliveira AC, Olivieri J, Oscier D, Panovska - Stavridis I, Papaioannou M, Papajik T, Kubova Z, Phumphukhieo P, Pierie C, Puiggros A, Rani L, Reda G, Rigolin GM, Ruchlemer R, Santos MDD, Schipani M, Schiwitz A, Shen YD, Simkovic M, Smirnova S, Soliman DSA, Spacek M, Tadmor T, Tomic K, Tse E, Vassilakopoulos T, Visentin A, Vitale C, von Tresckow J, Vrachliotis G, Vukovic V, Walewska R, Wasik - Szczepanek E, Xu ZS, Yagci M, Yañez L, Yassin M, Zuchnicka J, Angelopoulou M, Antic D, Biderman B, Catherwood M, Claus R, Coscia M, Cuneo A, Demirkan F, Espinet B, Gaidano G, Kalashnikova OB, Laurenti L, Nikitin E, Pangalis GA, Panagiotidis P, Popov VM, Pospisilova S, Sportoletti P, Stavroyianni N, Tam C, Trentin L, Chatzidimitriou A, Bosch F, Doubek M, Ghia P, Stamatopoulos K. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC the European Research Initiative on CLL in HARMONY. ECLINICALMEDICINE 2023 65 102307 10.1016/j.eclinm.2023.102307
 92. Visentin A, Chatzikonstantinou T, **Scarfò L***, Kapetanakis A, Demosthenous C, Karakatsoulis G, Minga E, Chamou D, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Besikli - Dimou S, Bron D, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar - García C, De Paoli L, De Paolis MR, Delgado J, Dimou M, Donaldson D, Catherwood M, Doubek M, Efsthathopoulou M, Eichhorst B, Elashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau J, García - Marco JA, Garcia - Serra R, Collado R, Gentile M, Gimeno E, Glenthøj A, da Silva MG, Hakobyan YK, Herishanu Y, Hernández - Rivas JA, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicinska E, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez - Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Rigolin GM, Ruchlemer R, Simkovic M, Spacek M, Sportoletti P, Stanca O, Tadmor T, Capasso A, Del Poeta G, Gutwein O, Karlsson LK, Milosevic I, Miras F, Reda G, Saghumyan G, Shrestha A, Raa DT, Tonino SH, Van Der Spek E, van Gelder M, van Kampen R, Wasik - Szczepanek E, Wróbel T, San Segundo LY, Yassin M, Pocali B, Vandenberghe E, Iyengar S, Varettoni M, Vitale C, Coscia M, Rambaldi A, Montserrat E, Cuneo A, Stavroyianni N, Trentin L, Stamatopoulos K, Ghia P. The evolving landscape of COVID - 19 and post - COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC the European research initiative on CLL. AMERICAN JOURNAL OF HEMATOLOGY 2023 98 12 1856 1868 10.1002/ajh.27093
 93. Moreno C, Solman IG, Tam CS, Grigg A, **Scarfò L**, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer - Glusman E, Choi M. Immune restoration with ibrutinib plus venetoclax in first - line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. BLOOD ADVANCES 2023 7 18 5294 5303 10.1182/bloodadvances.2023010236
 94. Sana I, Mantione ME, Meloni M, Riba M, Ranghetti P, **Scarfò L**, Ghia P, Muzio M. Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia. EUROPEAN JOURNAL OF IMMUNOLOGY 2023 53 10 10.1002/eji.202350418
 95. Moia R, Bergamo LD, Talotta D, Bomben R, Forestieri G, Spina V, Bruscaggini A, Cosentino C, Almasri M, Dondolin R, Bittolo T, Zucchetto A, Baldoni S, Del Giudice I, Mauro FR, Maffei R, Chiarenza A, Tafuri A, Laureana R, Del Principe MI, Zaja F, D'Arena G,

- Olivieri J, Rasi S, Mahmoud A, Al Essa W, Awikeh B, Kogila S, Bellia M, Mouhssine S, Sportoletti P, Marasca R, **Scarfò L**, Ghia P, Gattei V, Foa R, Rossi D, Gaidano G. XPO1 mutations identify early - stage CLL characterized by shorter time to first treatment and enhanced BCR signalling. *BRITISH JOURNAL OF HAEMATOLOGY* 2023 203 3 416 425 10.1111/bjh.19052
96. Sampietro M, Cassina V, Salerno D, Barbaglio F, Buglione E, Marrano CA, Campanile R, **Scarfò L**, Biedenweg D, Fregin B, Zamai M, Torres AD, Cantarero VL, Ghia P, Otto O, Mantegazza F, Caiola VR, Scielzo C. The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors. *HEMASPHERE* 2023 7 8 e931 10.1097/HS9.0000000000000931
 97. Visentin A, Mauro FR, **Scarfò L**, Gentile M, Farina L, Reda G, Ferrarini I, Proietti G, Derenzini E, Cibien F, Vitale C, Sanna A, Pietrasanta D, Marchetti M, Murru R, Rigolin GM, Sportoletti P, Trimarco V, Cavarretta CA, Angotzi F, Cellini A, Ruocco V, Zatta I, Laurenti L, Molica S, Coscia M, Ghia P, Foà R, Cuneo A, Trentin L. Continuous venetoclax in treatment - naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study. *AMERICAN JOURNAL OF HEMATOLOGY* 2023 98 9 E237 E240 10.1002/ajh.27009
 98. Rigolin GM, Olimpieri PP, Summa V, Celant S, **Scarfò L**, Tognolo L, Ballardini MP, Urso A, Sessa M, Gambarà S, Cura F, Fortini M, Ghia P, Cuneo A, Russo P. Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first - line ibrutinib: a nationwide registry study from the Italian Medicines Agency. *BLOOD CANCER JOURNAL* 2023 13 1 99 10.1038/s41408 - 023 - 00865 - z
 99. Bonfiglio S, Sutton LA, Ljungström V, Capasso A, Pandzic T, Weström S, Foroughi - Asl H, Skaftason A, Gellerbring A, Lyander A, Gandini F, Gaidano G, Trentin L, Bonello L, Reda G, Bödör C, Stavroyianni N, Tam CS, Marasca R, Forconi F, Panayiotidis P, Ringshausen I, Jaksic O, Frustaci AM, Iyengar S, Coscia M, Mulligan SP, Ysebaert L, Strugov V, Pavlovsky C, Walewska R, Österborg A, Cortese D, Ranghetti P, Baliakas P, Stamatopoulos K, **Scarfò L**^S, Rosenquist R, Ghia P. BTK and PLCG2 remain unmutated in one - third of patients with CLL relapsing on ibrutinib. *BLOOD ADVANCES* 2023 7 12 2794 2806 10.1182/bloodadvances.2022008821
 100. Laurenti L, **Scarfò L**, Frustaci AM, Sanna A, Iannella E, Caira M, Finsinger P, Schifano S, Neri B, Molica S, Mauro FR. Real - world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience. *HEMATOLOGICAL ONCOLOGY* 2023 41 4 621 630 10.1002/hon.3122
 101. Del Giudice I, Cappelli LV, Delgado J, Niemann CU, Andersen MA, Rotbain EHC, Aarup K, Walewska R, Visentin A, Deodato M, Frustaci AM, Cavalloni C, Gentile M, Yassin MA, Lad D, **Scarfò L**, Flogegard M, Mattsson M, Raponi S, Ilari C, Starza ID, Orlandi EM, Tedeschi A, Trentin L, Semenzato G, Guarini A, Ghia P, Montserrat E, Foà R. Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature. *BRITISH JOURNAL OF HAEMATOLOGY* 2023 201 2 353 356 10.1111/bjh.18696
 102. Mansouri L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, Meggendorfer M, Parker H, Nadeu F, Brieghel C, Laidou S, Moia R, Rossi D, Catherwood M, Kotaskova J, Delgado J, Rodríguez - Vicente AE, Benito R, Rigolin GM, Bonfiglio S, **Scarfò L**, Mattsson M, Davis Z, Gogia A, Rani L, Baliakas P, Foroughi - Asl H, Jylhä C, Skaftason A, Rapado I, Miras F, Martínez - Lopez J, de la Serna J, Rivas JMH, Thornton P, Larráyoza MJ, Calasanz MJ, Fésüs V, Mátrai Z, Bödör C, Smedby KE, Espinet B, Puiggros A, Gupta R, Bullinger L, Bosch F, Tazón - Vega B, Baran - Marszak F, Oscier D, Nguyen - Khac F, Zenz T, Terol MJ, Cuneo A, Hernández - Sánchez M, Pospisilova S, Mills K, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. *LEUKEMIA* 2023 37 2 504 504 10.1038/s41375 - 023 - 01813 - 3
 103. Innocenti I, Mosca A, Tomasso A, Galitzia A, **Scarfò L**, Morelli F, Galli E, Martini F, Sangiorgi E, Laureana R, Benintende G, Mattiello V, Chiriu S, Del Principe MI, Zamprogna G, Gentile M, Martino EA, Cappello E, Montalbano MC, Farina G, Innao V, Stirparo L, Patti C, Sportoletti P, Fresa A, Catania G, Coscia M, Bellesi S, Tedeschi A, Sanna A, Visentin A, Autore F, Pasquale R, Trentin L, Varettoni M, Ghia P, Murru R, Laurenti L. Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real - life experience. *HEMASPHERE* 2024 8 12 e144 10.1002/hem3.144
 104. Rigolin GM, Olimpieri PP, Summa V, Celant S, **Scarfò L**, Ballardini MP, Urso A, Gambarà S, Cavazzini F, Ghia P, Cuneo A, Russo P. Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study. *HEMASPHERE* 2024 8 10 e70017 10.1002/hem3.70017
 105. Chatzikonstantinou T, **Scarfò L**^{*}, Minga E, Karakatsoulis G, Chamou D, Kotaskova J, Iacoboni G, Demosthenous C, Albi E, Alcoceba M, Al - Shemari S, Aurran - Schleinitz T, Bacchiarri F, Chatzileontiadou S, Collado R, Davis Z, Santos MDD, Dimou M, Dmitrieva E, Donaldson D, Dos Santos G, Dreta B, Efstathiopoulou M, El - Ashwah S, Enrico A, Frygier A, Galimberti S, Galitzia A, Gimeno E, Guarente V, Guieze R, Harrop S, Hatzimichael E, Herishanu Y, Hernández - Rivas JA, Jaksic O, Kalicinska E, Laribi K, Karakus V, Kater AP, Kho B, Kislova M, Konstantinou E, Koren - Michowitz M, Kotsianidis I, Kubova Z, Labrador J, Lad D, Laurenti L, Longval T, Lopez - Garcia A, Marquet J, Maslejova S, Mayor - Bastida C, Mihaljevic B, Milosevic I, Miras F, Moia R, Morawska M, Nath UK, Navarro - Bailón A, Olivieri J, Panovska - Stavridis I, Papaioannou M, Pierie C, Puiggros A, Reda G, Rigolin GM, Ruchlemer R, Schipani M, Schiwitz A, Shen YD, Shokralla T, Simkovic M, Smirnova S, Soliman DSA, Stigenbauer S, Tadmor T, Tomic K, Tse E, Vassilakopoulos T, Visentin A, Vitale C, Vrachiolias G, Vukovic V, Walewska R, Xu ZS, Yagci M, Yañez L, Yassin M, Zuchnicka J, Oscier D, Gozzetti A, Panagiotidis P, Bosch F, Sportoletti P, Espinet B, Pangalis GA, Popov VM, Mulligan S, Angelopoulou M, Demirkan F, Papajik T, Biderman B, Murru R, Coscia M, Tam C, Cuneo A, Gaidano G, Claus R, Stavroyianni N, Trentin L, Antic D, Smolej L, Kalashnikova OB, Catherwood M, Spacek M, Pospisilova S, Doubek M, Nikitin E, Chatzidimitriou A, Ghia P, Stamatopoulos K. Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC the European Research Initiative on CLL. *HEMASPHERE* 2024 8 9 e70004 10.1002/hem3.70004
 106. Hägerstrand D, Oder B, Cortese D, Qu Y, ABP, Österholm C, Santos TD, Rabbani L, Asl HF, Skaftason A, Ljungström V, Lundholm A, Koutroumani M, Haider Z, Jylhä C, Mollstedt J, Mansouri L, Plevova K, Agathangelidis A, **Scarfò L**, Armand M, Muggen AF, Kay NE, Shanafelt T, Rossi D, Orre LM, Pospisilova S, Barylyuk K, Davi F, Vesterlund M, Langerak AW, Lehtiö J, Ghia P, Stamatopoulos K,

- Sutton LA, Rosenquist R. The non - canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1 - mutated chronic lymphocytic leukemia. *LEUKEMIA* 2024 38 11 2429 2442 10.1038/s41375 - 024 - 02379 - 4
107. Stamatopoulos K, Pavlova S, Al - Sawaf O, Chatzikonstantinou T, Karamanidou C, Gaidano G, Cymbalista F, Kater AP, Rawstron A, **Scarfò L**, Ghia P, Rosenquist R. Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities. *HEMASPHERE* 2024 8 7 e113 10.1002/hem3.113
108. Bordini J, Lenzi C, Frenquelli M, Morabito A, Pseftogas A, Belloni D, Mansouri L, Tsiolas G, Perotta E, Ranghetti P, Gandini F, Genova F, Hägerstrand D, Gavrilidis G, Keisaris S, Pechlivanis N, Davi F, Kay NE, Langerak AW, Pospisilova S, **Scarfò L**, Makris A, Psomopoulos FE, Stamatopoulos K, Rosenquist R, Campanella A, Ghia P. Ikbε deficiency accelerates disease development in chronic lymphocytic leukemia. *LEUKEMIA* 2024 38 6 1287 1298 10.1038/s41375 - 024 - 02236 - 4
109. Mauro FR, Scalzulli PR, **Scarfò L**, Minoia C, Murru R, Sportoletti P, Frigeri F, Albano F, Di Renzo N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C, Pennese E, Tafuri A, Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C, Ferrara F, Cuneo A, Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L, Varettoni M, Pane F, Liberati AM, Merli F, Morello L, Musuraca G, Tani M, Ibatici A, Regazzoni G, Di Candia M, Palma M, Arienti D, Molica S. Real - World Outcome of Treatment with Single - Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdENCE Study. *CANCERS* 2024 16 6 1228 10.3390/cancers16061228
110. Beyar - Katz O, Benjamini O, Delgado J, Ruella M, Ram R, Grisariu S, Visentin A, Vandenberghe E, Gentile M, Avigdor A, Shimoni A, Shouval R, Marcus R, Schuster SJ, Ortiz - Maldonado V, Ghilardi G, Paruzzo L, Zuckerman T, Tadmor T, Fineman R, Amit O, Martinez - Cibrian N, Gabrielli G, Avni B, Minga E, Shem - Tov N, **Scarfò L**, Yerushalmi R, Nagler A, Leiba R, Danylesko I, Stamatopoulos K, Chatzikonstantinou T, Ghia P, Herishanu Y. CD19 CAR T - Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia. *JOURNAL OF CELLULAR AND MOLECULAR MEDICINE* 2025; 29 (20). Doi: 10.1111/jcmm.70841
111. Visentin A, Gaffo E, Fürstenau M, Rogers KA, Panagiotis B, Cui CH, Miller C, Haferlach C, Plevova K, Oscier D, Davis Z, Nguyen - Khac F, Roncaglia E, Rigolin GM, Athanasiadou A, Baran - Marszak F, Valiente A, Terol MJ, Abrisqueta P, Espinet B, Puiggros A, Martines A, Bonaldi L, Mauro FR, **Scarfò L**, Chatzikonstantinou T, Tausch E, Kreuzer KA, Kater A, Bosch F, Doubek M, Panagiotidis P, Kalashnikova O, Frezzato F, Calabretto G, Ruocco V, Orsi S, Cellini A, Angotzi F, Serafin A, Yi SH, Eichhorst B, Woyach JA, Cuneo A, Ghia P, Stamatopoulos K, Trentin L, Bortoluzzi S. Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14,19): an ERIC study. *LEUKEMIA* 2025; 39 (12): 2957 - 2967.
112. Roncaglia E, Gaffo E, Calabretto G, Fürstenau M, Rogers KA, Baliakas P, Cui CH, Miller C, Haferlach C, Plevova K, Oscier D, Davis Z, Nguyen - Khac F, Rigolin GM, Athanasiadou A, Baran - Marszak F, Valiente A, Terol MJ, Abrisqueta P, Espinet B, Puiggros A, Martines A, Bonaldi L, Mauro FR, **Scarfò L**, Chatzikonstantinou T, Tausch E, Kreuzer KA, Kater A, Bosch F, Doubek M, Panagiotidis P, Kalashnikova O, Frezzato F, Ruocco V, Orsi S, Salek K, Merlo R, Caregari A, Glogovitis I, Cellini A, Angotzi F, Serafin A, Yi SH, Eichhorst B, Woyach JA, Cuneo A, Ghia P, Stamatopoulos K, Trentin L, Visentin A, Bortoluzzi S. Circular RNA signature of aggressive CLL with t(14,19)(q32,q13). An ERIC study. *JOURNAL OF HEMATOLOGY & ONCOLOGY* 2025; 18 (1). Doi: 10.1186/s13045 - 025 - 01725 - y
113. Serafin A, Cellini A, Martino EA, Mazzetto F, Angotzi F, Frustaci AM, Marchetti M, Moia R, Sanna A, Riemma C, Cibien F, Noto A, Lista E, Foglietta M, Vitale C, Innau V, Bullo M, Lovato E, Ferrarini I, Andriola C, Ballotta L, Innocenti I, Fresa A, Favrin G, Varettoni M, Santambrogio E, Orsucci L, Pasquale R, Moratti M, Laurenti L, Coscia M, Sportoletti P, Marasca R, Mauro FR, Patti C, Derenzini E, **Scarfò L**, Ghia P, Cuneo A, Tedeschi A, Trentin L, Gentile M, Visentin A. Venetoclax - based regimens in octogenarian patients with CLL: efficacy safety and comparison to BTKi in a multicenter cohort. *BLOOD ADVANCES* 2025; 9 (14): 3576 - 3584
114. Lenti E, Visentin E, Bojnjk E, Neroni A, Franchino M, Talarico D, Sacchetti N, **Scarfò L**, Maurizio A, Garcia - Manteiga JM, Ghia P, Brendolan A. A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia. *HEMASPHERE* 2025; 9 (7). Doi: 10.1002/hem3.70170
115. Blombery P, Chatzikonstantinou T, Gerousi M, Rosenquist R, Gaidano G, Pospisilova S, Roberts AW, Birkinshaw RW, Rossi D, **Scarfò L**, Seymour JF, Stilgenbauer S, Wiestner A, Woyach JA, Brown JR, Ghia P, Stamatopoulos K - Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice. *LEUKEMIA* 2025; 39 (9): 2049 - 2060
116. Serafin A, Sant'Antonio E, Mavilia F, Gandini F, De Pretis S, **Scarfò L**, Ghia P. Monoclonal B - Cell Lymphocytosis: The Silent Clone the Haematologists Should Not Neglect. *HEMATOLOGICAL ONCOLOGY* 2025; 43. Doi: 10.1002/hon.70084
117. Thorvaldsdottir B, Mansouri L, Sutton LA, Nadeu F, Meggendorfer M, Parker H, Brieghel C, Laidou S, Moia R, Rossi D, Kotaskova J, Delgado J, Rodríguez - Vicente AE, Benito R, Rigolin GM, Bonfiglio S, **Scarfò L**, Mattsson M, Davis Z, Baliakas P, Rapado I, Miras F, Martinez - Lopez J, de la Serna J, Rivas JMH, Larráyoz MJ, Calasanz MJ, Smedby KE, Espinet B, Puiggros A, Bullinger L, Bosch F, Tazón - Vega B, Baran - Marszak F, Oscier D, Nguyen - Khac F, Zenz T, Terol MJ, Cuneo A, Hernández - Sánchez M, Pospisilova S, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse - prognostic biomarker. *LEUKEMIA* 2025; 39 (7): 1650 - 1660.
118. Campanile R, Helenius J, Scielzo C, **Scarfò L**, Salerno D, Bossi M, Falappi M, Saponara A, Müller DJ, Mantegazza F, Cassina V. Production of AFM wedged cantilevers for stress - relaxation experiments: Uniaxial loading of soft spherical cells (vol 236 pg 1 2025) *METHODS* 2025 239 49 49 10.1016/j.ymeth.2025.03.013
119. Rompietti C, Adamo FM, Sorcini D, De Falco F, Stella A, Martino G, Bigerna B, Dorillo E, Barcelos ECS, Esposito A, Geraci C, Arcaleni R, Bordini J, **Scarfò L**, Rosati E, Ghia P, Falini B, Sportoletti P. Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice. *LEUKEMIA* 2025; 39 (5): 1157 - 1168.

120. Pseftogias A, Bordini J, Heltai S, Bonfiglio F, Gavrilidis G, Vasileiou V, Keisaris S, Belloni D, Taccetti C, Ranghetti P, Perotta E, Frenquelli M, Sarkar UA, Albi E, Martini F, Sant'Antonio E, Mavilia F, Psomopoulos F, Daibata M, Climent JAM, Mosialos G, Rossi D, Campanella A, **Scarfò L**, Stamatopoulos K, Xanthopoulos K, Ghia P. Loss of CYLD promotes splenic marginal zone lymphoma. *HEMASPHERE* 2025; 9 (3). Doi: 10.1002/hem3.70098
121. Campanile R, Helenius J, Scielzo C, **Scarfò L**, Salerno D, Bossi M, Falappi M, Saponara A, Müller DJ, Mantegazza F, Cassina V. Production of AFM wedged cantilevers for stress - relaxation experiments: Uniaxial loading of soft spherical cells. *METHODS* 2025; 236: 1 - 9.
122. Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland JB, Brieghel C, Andersen MK, Karypidou M, Biderman B, Doubek M, Lazarian G, Rapado I, Vynck M, Porret NA, Andres M, Rosenberg D, Sahar D, Martínez - Laperche C, Buño I, Hindley A, Donaldson D, Sánchez JB, García - Marco JA, Serrano - Alcalá A, Ferrer - Lores B, Fernández - Rodriguez C, Bellosillo B, Stilgenbauer S, Tausch E, Nikdin H, Quinn F, Atkinson E, van de Corput L, Yildiz C, Bilbao - Sieyro C, Florido Y, Thiede C, Schuster C, Stoj A, Czekalska S, Chatzidimitriou A, Laidou S, Bidet A, Dussiau C, Nollet F, Piras G, Monne M, Smirnova S, Nikitin E, Sloma I, Claudel A, Largeaud L, Ysebaert L, Valk PJM, Christian A, Walewska R, Oscier D, Sebastiao M, da Silva MG, Galieni P, Angelini M, Rossi D, Spina V, Matos S, Martins V, Stoklosa T, Pepek M, Baliakas P, Andreu R, Luna I, Kahre T, Murumets Ü, Pikousova T, Kurucova T, Laird S, Ward D, Alcoceba M, Balanzategui A, **Scarfò L**, Gandini F, Zapparoli E, Blanco A, Abrisqueta P, Rodríguez - Vicente AE, Benito R, Bravetti C, Davi F, Gameiro P, Martínez - Lopez J, Tazón - Vega B, Baran - Marszak F, Davis Z, Catherwood M, Sudarikov A, Rosenquist R, Niemann CU, Stamatopoulos K, Ghia P, Pospisilova S. Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC the European Research Initiative on CLL. *HEMASPHERE* 2025; 9 (1). Doi: 10.1002/hem3.70065
123. Innocenti I, Tomasso A, Giannarelli D, **Scarfò L**, Murru R, Visentin A, Frustaci AM, Morelli F, Vitale C, Mosca A, Sanna A, Farina G, Laureana R, Gentile M, Galizia A, Pasquale R, Autore F, Olivieri J, Romeo A, Deodato M, Stirparo L, Corbingi A, Innao V, Perutelli F, Martini F, Sportoletti P, Fresa A, Del Principe MI, Tedeschi A, Coscia M, Ghia P, Laurenti L. Acalabrutinib in High - Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real - Life Experience. *HEMATOLOGICAL ONCOLOGY* 2025; 43 (1). Doi: 10.1002/hon.70033
124. Kyrou D, Bonotis P, Kakalou C, Vasilopoulou M, **Scarfò L**, Meyerheim M, Sander A, Arpás T, Kazantzaki E, Maramis C, Karamanidou C. Perceptions and Needs of Stakeholders Regarding MyPal Project's Electronic Patient - Reported Outcome App: Cross - Sectional Qualitative Focus Group Study. *JMIR CANCER* 2025; 11. Doi: 10.2196/57388
125. Parker H, Mirandari A, Stevens B, Oquendo CJ, Duran - Ferrer M, Buermann L, Amarasinghe HE, Thomas J, Carr L, Syeda S, Sakthipakan M, Parry M, Rose - Zerilli MJ, Davis Z, McIver - Brown N, Xochelli A, Ennis S, **Scarfò L**, Ghia P, Kalpadakis C, Pangalis G, Rossi D, Gaidano G, Wagner S, Ahearne M, Seifert M, Plass C, Weichenhan D, Kimby E, Sutton LA, Rosenquist R, Amini RM, Ljungström V, Pratt G, Forconi F, Stamatopoulos K, Salido M, Ferrer A, Thieblemont C, Hilton L, Morin R, Walewska R, Martin - Subero JI, Oscier D, Oakes C, Gibson J, Bryant D, Strefford JC. Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance. *BLOOD ADVANCES* 2026; 10 (14); 4943 - 4957.
126. Chatzikonstantinou T, Vasilopoulou M, Kyrou D, Karakatsoulis G, Argyropaidas P, Besikli - Dimou S, Bonotis P, Chatzimina M, Didi J, Dimosthenous C, Garani - Papadatos T, Hoffman S, Kakalou C, Kazantzaki E, Kiefer S, Koumakis L, Ling J, Maramis C, Meyerheim M, Payne C, Papangelou C, Payne S, Pontikoglou C, Reston R, Ryblom H, Sander A, Schera F, Smedby KE, Zacharioudakis G, Chatzidimitriou A, Doubek M, Stavroyianni N, Ghia P, Papadaki HA, Rosenquist R, Graf N, Natsiavas P, Stamatopoulos K, Karamanidou C, **Scarfò L**. Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled Trial. *JCO ONCOLOGY PRACTICE* 2026; 22(7) 10.1200/OP - 25 - 00087
127. Belloni D, Barozzi D, Milani G, Barbaglio F, Puthukkunnath AR, Ranghetti P, Perotta E, Musco T, Sampietro M, Ponzoni M, **Scarfò L**, Ghia P, Scielzo C. A 3D lymph node model for chronic lymphocytic leukaemia recapitulates microenvironmental features and drug response in vitro. *DISEASE MODELS & MECHANISMS* 2026; 19 (6). Doi 10.1242/dmm.052731
128. Keramida K, Aznar MC, Bergler - Klein J, Boriani G, Cardinale D, Dent S, Drakaki A, Fuster JJ, Mamas MA, Okwuosa T, **Scarfò L**, van der Meer P, Yang EH, Lopez - Fernandez T. Sex Differences in Cancer and Cardiotoxicity: Mechanisms Outcomes and Clinical Implications Across Solid and Hematological Malignancies. *CANCERS* 2026; 18 (11). Doi 10.3390/cancers18111677
129. Mansouri L, Chatzikonstantinou T, **Scarfò L**, Rosenquist R. Therapy - driven clonal dynamics in chronic lymphocytic leukemia. *SEMINARS IN CANCER BIOLOGY* 2026; 122 (16). Doi: 10.1016/j.semcancer.2026.04.001
130. Palomba ML, Patel MR, Eyre TA, Jurczak W, Lewis D, Gastinne T, Ma S, Cohen JB, Patel K, Brown JR, **Scarfò L**, Munir T, Lech - Maranda E, Hoffmann MS, Ujjani CS, Fakhri B, Wang ML, Izutsu K, Nagai H, Tam CS, Rhodes JM, Vose J, McKinney M, Gerson JN, Barve MA, Kuss B, Koh Y, Barrett A, Treon SP, Castillo JJ, Seymour JF, Ruppert AS, McNeely SC, Walgren RA, Tsai E, Bao K, Nair B, Woyach J, Cheah CY. Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5 - year follow - up of the open - label multicentre phase 1/2 BRUIN trial. *LANCET HAEMATOLOGY* 2026; 13 (5); e284 - e296.
131. Molica S, Scalzulli PR, **Scarfò L**, Minoia C, Murru R, Sportoletti P, Albano F, Di Renzo N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C, Pennese E, Tafuri A, Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C, Ferrara F, Cuneo A, Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L, Varettoni M, Pane F, Merli F, Morello L, Musuraca G, Tani M, Ibatci A, Palma M, Arienti D, Mauro FR. Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real - World EVIdENCE Study. *CANCERS* 2026; 18 (6). Doi: 10.3390/cancers18061000
132. Cosentino C, Mouhssine S, Zucchetto A, Romano I, Salehi M, Cappelli LV, Iannelli F, Almasri M, Maher N, Fumagalli L, Cardinali D, Visentin A, Nabki J, Cividini L, Al Deeban B, Lazzaro M, Maiellaro F, Gaglio A, Perutelli F, Griggio V, Dondolin R, Bellia M, Nicolosi M, Rasi S, Secomandi E, Caneparo V, Mahmoud AM, Deambrogi C, Kogila S, Ghaneji J, Nawabi MR, Del Giudice I, Albi E, Vitale C,


Scarfò L, Coscia M, Trentin L, Pileri S, Ghia P, Chiarle R, Gattei V, di Bergamo LT, Rossi D, Foà R, Gaidano G, Moia R. Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation. HEMASPHERE 2026; 10 (2). doi: 10.1002/hem3.70322

133. Farina L, Noto A, Aiello A, Motta M, Ferrario A, Moia R, **Scarfò L**, Deodato M, Merli M, Ljevar S, Pruneri G, Carniti C, Corradini P. Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real - Life Study. HEMATOLOGICAL ONCOLOGY 2026; 44 (2). Doi: 10.1002/hon.70176
134. Chatzikonstantinou T, Mikhaleva M, Brieghel C, Papangelou C, Minga E, Arrais - Rodrigues C, Besikli - Dimou S, Cerutti A, Doubek M, Enggaard L, Espinet B, Ferrer - Lores B, Vela JAG, Gentile M, Vazquez EG, Gutwein O, Herishanu Y, Jablonowska - Babij P, Jaksic O, Josefsson P, Kalicinska E, Kislova M, Lista E, Kotsianidis I, Marquet J, Martino EA, McAuley C, Osorio MJM, Moia R, Mosquera C, Nikitin E, Pavlovsky MA, Pfister V, Comma EMS, **Scarfò L**, Sever M, Shvidel L, Simkovic M, Stavroyianni N, Talimtz P, Tranidou A, Visentin A, Vrachiolias G, Wasik - Szczepanek E, Wróbel T, Yagci M, Cellini A, Chatzidimitriou A, Gaidano G, Anderson MA, Davids MS, Brown JR, Niemann CU, Stamatopoulos K, Ghia P, Ahn IE, Koren - Michowitz M. Central nervous system involvement in CLL: an international retrospective study by ERIC the European Research Initiative on CLL BLOOD ADVANCES 2026; 10 (2); 428 - 438.
135. Al - Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindström V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha - Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Böttcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, **Scarfò L**, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Sema J, Loscertales J, Lindblad O, Sandstedt AB, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M. Fixed - Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE 2026; 394 (11); 1084 - 1096.

* shared first authorship

§ shared last authorship

Milano, September 1st, 2026

 01SEP2026

I authorize the use of my personal data in compliance with Legislative Decree 196/03.

Milano, September 1st, 2026

I authorize the publication of the CV on the SIES website.